Comparative evaluation of the effectiveness of resveratrol and quercetin in patients with coronary heart disease according to daily holter monitoring of electrocardiogram
Abstract
. The leading cause of death in the world remains Coronary Heart Disease (CHD), despite the many treatments being developed. Therefore, the search for new effective methods of treating CHD is extremely relevant. One of the pathogenetic mechanisms of atherosclerosis progression, which is the morphological basis of CHD, is chronic systemic inflammation. Anti-inflammatory activity at different levels of pro-inflammatory signaling has polyphenols of plant origin, which determined the direction of our scientific search. A prospective open-label randomized controlled trial was conducted in 108 people with CHD, I-II functional class (FC), with heart failure I-II FC. After analyzing the results of daily Holter monitoring (HM) of electrocardiogram (ECG), patients were randomized to 2 study groups and a comparison group. Along with the basic therapy of CHD
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 108 participants or records.
Read the paper
Related studies
- Quercetin Influences Quorum Sensing in Food Borne Bacteria: In-Vitro and In-Silico Evidence
- Phenolic-protein interactions: insight from in-silico analyses – a review
- In Silico Discovery of Candidate Drugs against Covid-19
- Neuropharmacological Effects of Quercetin: A Literature-Based Review
- In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting
- Effect of Quercetin Rich Onion Extracts on Bacterial Quorum Sensing
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.